Background-Ranolazine is a novel antianginal shown in an exploratory analysis in patients with diabetes mellitus and chronic angina to be associated with a decline in hemoglobin A 1c (HbA 1c ). We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial. Methods and Results-We compared HbA 1c (percentage) and the time to onset of a Ն1% increase in HbA 1c among 4918 patients with acute coronary syndrome randomized to ranolazine or placebo in the MERLIN-TIMI 36 trial. Ranolazine significantly reduced HbA 1c at 4 months compared with placebo (5.9% versus 6.2%; change from baseline, Ϫ0.30 versus Ϫ0.04; PϽ0.001). In patients with diabetes mellitus treated with ranolazine, HbA 1c declined from 7.5 to 6.9 (change from baseline, Ϫ0.64; PϽ0.001). Diabetic patients were more likely to achieve an HbA 1c Ͻ7% at 4 months with ranolazine compared with placebo (59% versus 49%; PϽ0.001) and were less likely to have a Ն1% increase in HbA 1c (14.2% versus 20.6% at 1 year; hazard ratio, 0.63; 95% confidence interval, 0.51 to 0.77; PϽ0.001). Moreover, ranolazine reduced recurrent ischemia in diabetic patients (hazard ratio, 0.75; 95% confidence interval, 0.61 to 0.93; Pϭ0.008). Notably, in patients without diabetes mellitus at baseline, the incidence of new fasting glucose Ͼ110 mg/dL or HbA 1c Ն6% was reduced by ranolazine (31.8% versus 41.2%; hazard ratio, 0.68; 95% confidence interval, 0.53 to 0.88; Pϭ0.003). Reported hypoglycemia did not increase with ranolazine (PϭNS). Conclusions-Ranolazine significantly improved HbA 1c and recurrent ischemia in patients with diabetes mellitus and reduced the incidence of increased HbA 1c in those without evidence of previous hyperglycemia. The mechanism of this effect is under investigation.
D iabetes mellitus (DM) is a global health challenge marked by a steady rise in worldwide prevalence 1 and substantial associated cardiovascular morbidity and mortality. 2 On the basis of data from the Centers for Disease Control Diabetes Surveillance System, it has been estimated that Ϸ30% of individuals with DM 35 to 64 years of age have cardiovascular disease and that this proportion is as high as 45% among DM patients 65 to 74 years of age. 3 Nearly 3 million Americans have been diagnosed with DM and coronary artery disease, and the incidence of DM appears to be increased in patients with acute coronary syndrome, who often manifest abnormal glucose me-tabolism at presentation. 3, 4 The presence of DM is associated with poorer outcomes in patients with stable and unstable coronary artery disease. 2, 5 Moreover, the number of individuals whose prognosis is impaired in association with dysglycemia is substantially larger when those with impaired glucose metabolism, a progenitor of DM, are considered. 6 Aimed at preventing microangiopathy, neuropathy, and possibly macrovascular disease, treatment of hyperglycemia is a key goal of secondary preventive therapy, with a target of reducing hemoglobin A 1c (HbA 1c ) to Յ7%, in patients with atherosclerosis. [7] [8] [9] 
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Ranolazine, a novel oral antianginal agent, became available in the United States in 2006 for the treatment of selected patients with chronic angina. 10 It improves exercise performance and reduces the frequency of angina in patients with stable angina. 11, 12 Intriguingly, in an exploratory analysis from a trial in patients with chronic angina, ranolazine was found to be associated with a significant reduction in HbA 1c . 13 We recently reported the primary results of the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial, which showed that ranolazine reduced recurrent ischemia in a substantially broader population than previously studied and that its electrophysiological effects were associated with a significant reduction rather than an increase in arrhythmias. 14 -16 As part of the trial design, we prospectively planned to evaluate the effect of ranolazine on HbA 1c and clinical outcomes among patients with DM in this multinational, randomized, placebo-controlled trial. 14
Methods

Patient Population
The study design, investigators, and primary results of the MERLIN-TIMI 36 trial have been published previously. 14, 15 Between 2004 and 2006, 6560 patients with non-ST-elevation acute coronary syndrome with at least 1 indicator of moderate to high risk of recurrent ischemic events underwent randomization at 440 sites in 17 countries. Major exclusion criteria included cardiogenic shock, clinically significant hepatic disease, end-stage renal disease, treatment with agents known to prolong the QT interval, or a life expectancy of Ͻ12 months. 14 The protocol was approved by the relevant institutional review boards at all participating centers. Written informed consent was obtained from all patients.
Study Procedures
Eligible patients were randomly assigned in a 1:1 ratio to receive either ranolazine or placebo initiated as an intravenous infusion and followed by oral administration at a dose of 1000 mg twice daily until the end of the study, except in cases of a protocol-specified reduction in dose (eg, for patients with new renal insufficiency or persistent prolongation of the QT interval). 14 Randomization was stratified according to the responsible physician's intended initial management strategy (early invasive versus conservative), declared at the time of randomization. Patients returned for study visits at 14 days and 4 months and every 4 months thereafter until the end of the study visit for each subject. 15 A history of DM and its treatment were established by physician's diagnosis and review of medical records and were recorded by the investigator on the case record form. The protocol stipulated that HbA 1c and plasma glucose were to be measured locally at baseline (median, 24 hours after symptom onset), 4 months, 8 months, 16 months, and the final study visit, with data recorded in the case report form as to whether the patient fasted before sampling. An oral glucose tolerance test was to be performed at the 8-month or final visit (whichever came sooner) in patients without documented DM. The oral glucose tolerance test was performed after an 8-to 14-hour fast with a standard oral load of 75 g glucose in 250 to 300 mL water with glucose determinations at baseline and at 2 hours. Metabolic syndrome at enrollment was defined by the presence of any 3 of the following: (1) waist circumference Ͼ102 cm (men) and Ͼ88 cm (women); (2) serum triglycerides Ͼ150 mg/dL or drug treatment for elevated triglycerides; (3) high-density lipoprotein cholesterol Ͻ40 mg/dL (men) and Ͻ50 mg/dL (women) or drug treatment for reduced high-density lipoprotein cholesterol; (4) systolic blood pressure Ͼ130 mm Hg, diastolic blood pressure Ͼ85 mm Hg, or drug treatment for hypertension; and (5) fasting glucose Ͼ100 mg/dL. Although prespecified, the glycometabolic testing was ancillary to the main clinical objectives of the protocol; thus, we did not anticipate having data for the complete cohort. All available data were included in the analyses except for a single implausible value of 41.6%. HbA 1c values were not available predominantly because the patient declined, because the patient withdrew from the main study, or for logistical reasons in 984 patients at baseline, 1692 at 4 months, 1247 at 8 months, and 1082 at the final visit.
End Points
An end point of worsening hyperglycemia was defined as a Ն1% increase in HbA 1c . In the absence of a history of DM at enrollment, new DM was defined by any of the following: fasting plasma glucose Ն126 mg/dL at Ͼ14 days after enrollment, plasma glucose Ն200 mg/dL at 2 hours after the glucose load during an oral glucose tolerance test, or new DM reported by the investigator. New hyperglycemia in those with no laboratory evidence of prior dysglycemia was defined as fasting glucose Ͼ110 mg/dL or HbA 1c Ն6% in those patients with fasting glucose Ͻ100 mg/dL and HbA 1c Ͻ6% at baseline. Oral glucose tolerance test data at 0 and 2 hours were available for 3195 patients. Each of these diabetes-related end points was defined in a statistical analysis plan that was finalized before locking of the database and examination of the data. An exploratory analysis based on the cut point from professional guidelines 7-9 for patients with DM was performed to determine the proportion of patients with DM and HbA 1c Ͻ7% at each visit.
The major cardiovascular efficacy and safety end points have been described in detail. 14 The primary efficacy end point of the trial was the first occurrence of any element of the composite of cardiovascular death, myocardial infarction, or recurrent ischemia. Given the established indication for ranolazine as an antianginal agent, we also separately evaluated the incidence of recurrent ischemia and the composite end point of cardiovascular death or myocardial infarction. 14, 15 The average duration of follow-up was 348 days.
Statistical Analyses and End Points
Baseline clinical characteristics are reported using the median and 25th and 75th percentiles for continuous variables and proportions for categorical characteristics. HbA 1c and glucose data are reported as least-squares mean estimates. Analyses of HbA 1c and other laboratory measurements and safety assessments were conducted using the actual treatment received (a single dose or more). All cardiovascular efficacy analyses were conducted according to the intention-to-treat principle. HbA 1c and glucose values were compared between treatment groups using a generalized linear mixedeffects model (SAS PROC GENMOD), assuming an exchangeable working correlation matrix, with effects for treatment, intention for early invasive management, time, and the interaction term for treatment by time. Interactions with baseline glycemic status were tested with the addition of interaction terms. Simple Pearson correlation coefficients also were calculated.
Time-to-event analyses were performed using the log-rank test stratifying by the intention to use an early invasive strategy. Hazard ratios (HRs) and 95% confidence limits were estimated with a Cox proportional-hazards model (SAS PROC PHREG) with effects for treatment and stratified by intention for early invasive strategy. Event rates, including the cumulative incidence of worsening hyperglycemia, are presented as Kaplan-Meier failure rates at 12 months. Exploratory analyses were conducted among the subgroups of patients with and without metabolic syndrome, including those with evidence of hyperglycemia but without prior diagnosis of diabetes, given prior evidence for the higher likelihood of progression of dysglycemia in these groups. 6 The investigators had full access to the data. The raw database was provided to the TIMI Study Group, and all analyses reported here were carried out independently by the TIMI Study Group; study group members wrote this report and take full responsibility for the data. All authors have read and agree to the manuscript as written.
Analyses were conducted with STATA SE 9.2 (Stata Corp, College Station, Tex) and SAS 9.1 (SAS Institute, Inc, Cary, NC).
Results
Of the 6560 patients enrolled in the MERLIN-TIMI 36 trial, 2220 (33.8%) had a history of DM. Evaluation of HbA 1c at enrollment (nϭ5576) in those with (nϭ1950) and without (nϭ3626) a history of DM revealed a substantially higher proportion of patients (49%) with evidence of chronic hyperglycemia (HbA 1c 6.0 to Ͻ6.5%, 898 [16%]; HbA 1c 6.5 to Ͻ7.0%, 497 [9%]; HbA 1c Ն7.0%, 1343 [24%]). Among patients without previously diagnosed DM, 466 (13%) had a baseline HbA 1c Ն6.5%. In addition, 271 (6%) of patients without recognized DM had a baseline fasting glucose Ͼ126 mg/dL or casual glucose Ն200 mg/dL.
Among patients with DM with available diabetes treatment data (nϭ2028), a total of 578 (29%) were treated with insulin with or without oral agents, 1127 (56%) with oral agents without insulin, and 253 (12%) with dietary intervention alone; 70 patients (3%) were reported as receiving no treatment. Among patients treated with oral agents, 404 (36%) were managed with Ն2 agents before hospitalization for the qualifying event.
Effect of Ranolazine on HbA 1c
All Patients Serial determinations of HbA 1c at baseline and any subsequent time point were available for 4918 patients. Baseline characteristics were well balanced among those in this subgroup randomized to ranolazine compared with placebo (the Table) . Their clinical characteristics were qualitatively similar to those without HbA 1c data (Table in the online-only Data Supplement). At baseline, the concentration of HbA 1c was 6.2% in both groups, and the use of insulin and oral hypoglycemic agents was well balanced (the Table) . In the overall population, HbA 1c (ϮSEM) was significantly lower at 4 months in patients treated with ranolazine (5.9Ϯ0.03%) compared with placebo (6.2Ϯ0.03%); absolute change from baseline was Ϫ0.30Ϯ0.03% with ranolazine compared with Ϫ0.04Ϯ0.03% with placebo (PϽ0.001). 
Patients With Previously Diagnosed DM
Among patients previously diagnosed with DM, by 4 months, HbA 1c declined by an absolute 0.64% (7.5% to 6.9%; Figure 1 ) in patients treated with ranolazine compared with a 0.22% decline (7.4% to 7.2%) in those treated with placebo (PϽ0.001 for ranolazine versus placebo 
Patients Without Previously Diagnosed DM
Notably, an effect of ranolazine on HbA 1c was also apparent in those patients without a history of DM. By 4 months, a statistically significant, albeit small, decline in HbA 1c was found in patients allocated to ranolazine (change from baseline, Ϫ0.12Ϯ0.03; PϽ0.001) compared with a rise in HbA 1c in patients without a history of DM allocated to placebo (change from baseline, 0.06Ϯ0.02; Pϭ0.02), resulting in a significant difference between treatment groups (PϽ0.001; Figure 1 ). The effect of ranolazine on HbA 1c , although statistically significant, was smaller in those without compared with those with DM (P for interactionϽ0.001 
Other Glycometabolic Parameters
Examination of the change in plasma glucose in all patients with available samples (Figure 2) 
Clinical Efficacy and Safety of Ranolazine as an Antianginal Agent in Patients With DM
Consistent with the results in the overall cohort (HR, 0.87; 95% CI, 0.76 to 0.99), 14, 15 treatment with ranolazine in patients with DM resulted in a significant reduction in recurrent ischemia (HR, 0.75; 95% CI, 0.61 to 0.93; Pϭ0.008; Figure 3 ) with borderline statistical evidence of heterogeneity compared with patients without DM (HR, 0.95; 95% CI, 0.80 to 1.11; P for interactionϭ0.10) and did not affect the risk of cardiovascular death or myocardial infarction (HR, 1.09; 95% CI, 0.86 to 1.38; Pϭ0.46; P for interactionϭ0.29).
Among patients with DM treated with ranolazine, no excess of death resulting from any cause (HR, 0.98; 95% CI, 0.70 to 1.36; Pϭ0.89; P for interactionϭ0.91) or sudden cardiac death (HR, 0.76; 95% CI, 0.41 to 1.39; Pϭ0.37) was found compared with those treated with placebo. The incidence of new or worsening heart failure also did not differ with ranolazine versus placebo (HR, 1.01; 95% CI, 0.73 to 1.39; Pϭ0.95; P for interactionϭ0.68). As in the overall cohort, the incidence of ventricular tachycardia (Ն8 beats) observed during Holter monitoring in patients with DM year in patients allocated to ranolazine versus placebo stratified by diabetes status. Testing for heterogeneity revealed no significant difference in the effect of ranolazine between patients with and without CM (P for interactionϭ0.10).
(nϭ2152) was lower in the ranolazine group (4.7%) compared with the placebo group (6.8%; Pϭ0.037).
Discussion
The results of this prospectively planned analysis from a large, randomized, double-blind, placebo-controlled trial establish that the novel antianginal agent ranolazine reduces HbA 1c in patients with DM and may mitigate new hyperglycemia in patients at risk for DM. At the same time, we provide evidence for the consistent antianginal effects and the cardiovascular and overall safety of ranolazine among patients with DM and high-risk coronary artery disease. Together, these 2 findings point toward ranolazine as an attractive antianginal agent for patients with chronic angina and impaired glucose metabolism.
Effects of Ranolazine on Hyperglycemia
Ranolazine has been shown to exert its anti-ischemic and antianginal actions without effects on heart rate or blood pressure. 10 Initial evidence supporting ranolazine as a metabolic modulator 17 sparked interest in its potential for favorably influencing hyperglycemia. In an exploratory analysis among 131 patients with chronic angina, DM, and serial determinations of HbA 1c in the Combination Assessment of Ranolazine in Stable Angina (CARISA) trial, ranolazine was shown to be associated with statistically significant 0.50% and 0.72% absolute declines in HbA 1c by 12 weeks with dosing of 750 and 1000 mg BID, respectively, compared with a Ϫ0.02% change in the placebo group. 13 Our prospective analysis in the much larger population with serial HbA 1c from MERLIN-TMI 36 demonstrates a 0.64% decline in HbA 1c at 16 weeks in patients with DM receiving ranolazine compared with 0.24% in those receiving placebo. Moreover, in the present study, the significant reduction in HbA 1c with ranolazine was observed despite a relatively low mean HbA 1c in patients with DM at baseline (7.5%) and the unrestricted clinical management of hyperglycemia in both of the blinded treatment groups. Long-term comparable changes in HbA 1c are associated with a decrease in the incidence of microvascular complications of DM. 18 It is not surprising, given the relatively short duration of follow-up, that any impact of improved HbA 1c with ranolazine on macrovascular events was not seen in this study.
Despite these intriguing findings with respect to the influence of ranolazine on the concentration of HbA 1c , additional studies are needed to establish the pathobiological mechanisms underlying this consistent epidemiological observation. On the basis of findings from experimental models, the mechanism of action of ranolazine as an antianginal agent was initially proposed to be through partial inhibition of fatty acid oxidation, resulting in a shift of cellular metabolism toward the more oxygen-efficient use of glucose. 17 However, subsequent research has demonstrated this effect on substrate use to occur only at concentrations substantially higher than those at which ranolazine is observed to have its clinical effect on angina. 10 Concurrently, at concentrations similar to that achieved with its clinically approved dosing (500 to 1000 mg twice daily), ranolazine has been shown inhibit the slowly inactivating component of the cardiac sodium current (late I Na ). 19 By preventing cellular sodium and calcium overload, ranolazine reduces myocyte dysfunction and may reduce myocardial wall stress, oxygen consumptions, and microvascular compression, thereby favorably altering the balance between myocardial oxygen supply and demand. 10 These actions of ranolazine do not offer an immediate explanation for its effect on HbA 1c . However, preliminary findings from experimental models demonstrated that ranolazine increased glucose-stimulated insulin secretion in isolated pancreatic islets and in awake rats after an intravenous glucose load. 20 This observation points to a possible role for ion channels on pancreatic ␤ cells in the secretion of insulin. Whether these findings are due to the effects on sodium channels and indirectly on intracellular adenosine triphosphate and calcium remains to be determined. The theoretical possibilities that ranolazine may shorten erythrocyte lifespan or inhibit glucuronidation of hemoglobin, thereby influencing HbA 1c without altering glycemic control, may be considered unlikely because no effect of ranolazine on hematocrit was found, and the only potential adduct of ranolazine (2,6dimethyl aniline) that could plausibly interfere with glucuronidation of hemoglobin is not a metabolite of ranolazine in humans. In addition, exploratory analyses in this study indicated that ranolazine significantly strengthened the relationship between change in nonfasting glucose and change in HbA 1c , lending some support to the hypothesis from preclinical findings that ranolazine may reduce HbA 1c through increased glucose-stimulated insulin secretion. Nevertheless, additional investigations of the mechanism underlying our observations are needed to corroborate a clinically meaningful effect of ranolazine on glucose homeostasis in humans.
Study Limitations
Because this study, albeit prospectively designed, was ancillary to the main objectives for MERLIN-TIMI 36, data for HbA 1c and glucose could not be obtained for all subjects, and diabetes status at enrollment was based on patient history. Moreover, the timing and conditions of glucose measurement were not controlled. Thus, missing data may adversely affect the generalizability of our findings. Nevertheless, because the reasons for missing data are expected to be largely random in nature, any impact on the qualitative conclusions may reasonably be anticipated to be small. In addition, the lack of controlled timing of glucose measurements may have contributed to the lack of a significant difference in glucose measurements in our study. Because testing for HbA 1c was performed with locally available assays, the absolute change in HbA 1c observed reflects the distribution of assays used and cannot be referenced to a single reference assay. For these reasons, additional studies designed specifically to assess the glycometabolic effects of ranolazine are needed to corroborate the clinical applicability of our findings.
Potential Clinical Implications
If supported by ongoing mechanistic studies and additional studies designed with a focus on glycometabolic effects, the finding of a significant favorable effect of ranolazine on glycemia could be of clinical importance. The overlapping presentation of coronary artery disease and DM is common-place and is increasing with the prevalence of obesity worldwide. Although achieving an HbA 1c concentration Ͻ7% is established as a guideline for secondary prevention among patients with established coronary artery disease, 7 data from the National Health and Nutrition Examination Survey indicate that Ͻ50% of patients with DM achieve this goal. 21 Therefore, there continues to be a strong interest in new agents to manage hyperglycemia in this patient population. 22 In addition, the cardiovascular safety of some oral hypoglycemic agents has been challenged, with experts pointing to a need for adequately powered clinical outcomes trials. [23] [24] [25] Moreover, the adverse glycometabolic effects of ␤1-selective ␤-blockers are a consideration in patients with DM. Thus, an effective antianginal agent with established cardiovascular and overall safety in a large outcomes trial that increases the proportion of patients meeting current goals for management of hyperglycemia would have particular appeal for the treatment of angina in this high-risk population.
Conclusions
Ranolazine significantly lowered HbA 1c in patients with established coronary artery disease and DM and reduced the incidence of increased HbA 1c in those without evidence of previous hyperglycemia. The mechanism of this effect is under investigation.
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